In severe eosinophilic asthma controlled with benralizumab, tapering high-dose ICS reduced dose while maintaining...

Area of Science:

• Pulmonology
• Clinical Trials
• Pharmacology

Background:

• Severe eosinophilic asthma is often associated with frequent exacerbations and reliance on high-dose inhaled corticosteroids (ICS).
• Reducing ICS burden is crucial to minimize long-term side effects while maintaining asthma control.
• Benralizumab is an interleukin-5 receptor alpha antagonist targeting eosinophilic inflammation.

Purpose of the Study:

• To evaluate the feasibility and efficacy of reducing daily maintenance ICS doses in patients with severe eosinophilic asthma treated with benralizumab.
• To assess the impact of ICS reduction on asthma control, exacerbations, and lung function.

Main Methods:

• A randomized, multicenter, open-label, phase 4 study (SHAMAL) involving patients with severe eosinophilic asthma.
• Participants received benralizumab and underwent a structured protocol for reducing daily maintenance ICS.
• Primary endpoints included the proportion of patients achieving ICS reduction and maintaining asthma control.

Main Results:

• A significant proportion of patients successfully reduced their daily ICS maintenance dose while on benralizumab therapy.
• Benralizumab treatment was associated with sustained asthma control and reduced exacerbation rates during ICS reduction.
• No significant decline in lung function was observed in patients undergoing ICS reduction.

Conclusions:

• Benralizumab facilitates a reduction in daily maintenance ICS in patients with severe eosinophilic asthma.
• This approach may help mitigate ICS-related comorbidities and improve patient quality of life.
• Benralizumab represents a valuable therapeutic option for managing severe eosinophilic asthma and enabling ICS de-escalation.